Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis

BMC Cancer

Volumn 9, Issue , 2009, Pages

  McLaughlin, Patricia J ^a   Zagon, Ian S ^a   Park, Sunny S ^a   Conway, Andrea ^a   Donahue, Renee N ^a   Goldenberg, David ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METENKEPHALIN; METHIONINE ENKEPHALIN RECEPTOR; METHIONINE-ENKEPHALIN RECEPTOR; OPIATE RECEPTOR;

ADENOCARCINOMA; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, FOLLICULAR; CELL LINE, TUMOR; CELL PROLIFERATION; ENKEPHALIN, METHIONINE; HUMANS; RECEPTORS, OPIOID; THYROID NEOPLASMS;

EID: 74049119293     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-369     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2003, 55:74-108.
3. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999, 16:64-69. 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.0.CO;2-U, 9890741.
4. Tann R, Finlay R, Driscoll D. Anaplastic carcinoma of the thyroid: a 24 year experience. Head Neck 1995, 17:41-48. 10.1002/hed.2880170109, 7883548.
5. Blankenship DR, Chin E, Terris DJ. Contemporary management of thyroid cancer. Amer J Otolaryngol - Head Neck Med Surg 2005, 26:249-260.
6. Sarlis NJ. Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: Basic aspects. Rev Endo Metab Disorders 2000, 1:183-196.
7. Harnsberger HR, Hudgins PA, Wiggins RH. Anaplastic thyroid carcinoma. Diagnostic Imaging: Head and Neck 2004, Salt Lake City: Amirsys, Harnsberger HR, Hudgins PA, Wiggins RH III.
8. Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J, Remick S. Phase II study of combretaastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC)[abstract]. J Clin Oncol 2005, 24:300S.
9. Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In vivo and microarray analysis of rexinoid-response anaplastic thyroid carcinoma. Clin Cancer Res 2008, 14:589-596. 10.1158/1078-0432.CCR-07-0269, 18223235.
10. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metabol 2007, 92:2902-2909. 10.1210/jc.2007-0027.
11. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 1997, 82:1857-1862. 10.1210/jc.82.6.1857, 9177396.
12. Ball DW, Jin N, Rosen M, Dackiw A, Sidransky D, Xing M, Nelkin BD. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007, 92:4712-4718. 10.1210/jc.2007-1184, 17878251.
13. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, Myers JN. The tyrosine kinase inhibitor ASD inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 2171, 13:4519-4527.
14. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 1999, 14:991-998.
15. McLaughlin PJ, Stack BC, Braine KM, Ruda JD, Zagon IS. Opioid growth factor (OGF) inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol 2004, 24:227-232.
16. McLaughlin PJ, Stack BC, Levin RJ, Fedok F, Zagon IS. Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer 2003, 97:1701-1710. 10.1002/cncr.11237, 12655527.
17. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999, 14:577-584.
18. Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 1996, 271:R511-R518.
19. Bisignani GJ, McLaughlin PJ, Ordille SD, Jarowenko MJ, Zagon IS. Human renal cell proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 1999, 162:2186-2191. 10.1016/S0022-5347(05)68157-8, 10569617.
20. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 2000, 17:1053-1061.
21. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res 2007, 67:10511-10518. 10.1158/0008-5472.CAN-07-1922, 17974995.
22. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 2007, 7:5-17.
23. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Res 2002, 38:351-376.
24. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med 2008, 233:968-979.
25. Zagon IS, Donahue RN, McLaughlin PJ. The OGF-OGFr axis is a determinant of cell proliferation in diverse human cancers. Amer J Physiol 2009, 297:R1154-R1161.
26. McLaughlin PJ, Verderame MF, Hankins JL, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med 2007, 19:421-428.
27. Zagon IS, Verderame MF, Hankins JL, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol 2007, 30:775-783.
28. Zagon IS, Kreiner S, Heslop JJ, Conway AB, Morgan CR, McLaughlin PJ. Prevention and delay in progression of human pancreatic cancer by overexpression of the opioid growth factor receptor (OGFr). Int J Oncol 2008, 33:317-323.
29. McLaughlin PJ, Kreiner S, Morgan CR, McLaughlin PJ. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor (OGFr). Int J Oncol 2008, 33:751-757.
30. Goldenberg D, Zagon IS, Fedok F, Crist H, McLaughlin PJ. The presence of opioid growth factor (OGF) - OGF receptor (OGFr) axis in human non-medullary thyroid cancer. Thyroid 2008, 18:1165-1170. 10.1089/thy.2008.0112, 19014324.
31. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, Sonoo H. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000, 85:2889-2896. 10.1210/jc.85.8.2889, 10946899.
32. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen RB. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93:4331-4341. 10.1210/jc.2008-1102, 18713817.
33. Zagon IS, Sassani JW, Allison G, McLaughlin PJ. Conserved expression of the opioid growth factor, [Met5]-enkephalin, and the zeta (ζ) opioid receptor in vertebrate cornea. Brain Res 1995, 671:105-111. 10.1016/0006-8993(94)01314-8, 7728521.
34. Zagon IS, McLaughlin PJ. Production and characterization of polyclonal and monoclonal antibodies to zeta (ζ) opioid receptor. Brain Res 1993, 630:295-302. 10.1016/0006-8993(93)90669-E, 8118696.
35. Zagon IS, Ruth TB, McLaughlin PJ. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat Rec A: Discov Mol Cell Evol Biol 2005, 282:24-37.
36. Zagon IS, McLaughlin PJ. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003, 37:79-88. 10.1016/S0143-4179(03)00007-6, 12747939.